Impact of Vascular Calcifications on Long Femoropopliteal Stenting Outcomes

被引:13
|
作者
Kaladji, Adrien [1 ,2 ,3 ]
Vent, Pierre-Alexandre [4 ]
Danvin, Aurore [4 ,5 ]
Chaillou, Philippe [4 ]
Costargent, Alain [4 ]
Guyomarch, Beatrice [6 ,7 ,8 ]
Quillard, Thibaut [5 ]
Goueffic, Yann [4 ,5 ,8 ]
机构
[1] Rennes Univ Hosp, Ctr Cardiothorac & Vasc Surg, F-35033 Rennes, France
[2] INSERM, U1099, Rennes, France
[3] Univ Rennes 1, Signal & Image Proc Lab LTSI, Rennes, France
[4] Nantes Univ Hosp, Thorax Inst, Dept Vasc Surg, Nantes, France
[5] Lab Pathophysiol Bone Resorpt, UMR 957, Nantes, France
[6] INSERM, UMR1087, Thorax Inst, Nantes, France
[7] CNRS, UMR 6291, Nantes, France
[8] Univ Nantes, Nantes, France
关键词
PACLITAXEL-ELUTING STENTS; ATHEROSCLEROTIC LESIONS; ARTERIAL CALCIFICATION; COMPUTED-TOMOGRAPHY; COATED BALLOON; CAP RUPTURE; TASC C; PLAQUE; ANGIOPLASTY; PREVALENCE;
D O I
10.1016/j.avsg.2017.08.043
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Vascular calcifications (VCs) may be a prognostic factor for outcome after endovascular treatment of peripheral arterial disease (PAD). Semiquantitative analysis with X-ray imaging is the main limiting factor for assessing VCs. The aim of the present study was to find a correlation between the amount of VC with computed tomography (CT) scan quantification and midterm results of endovascular treatment of Trans-Atlantic Inter-Society Consensus C/D femoropopliteal (FP) lesions. Methods: Patients belonging to 2 previously published registries (STELLA and STELLA PTX) and who underwent a preoperative CT scan were retrospectively included in the study. VC quantification was performed with a dedicated workstation (EndoSize, Therenva) on the basis of Hounsfield units (HU). The VC percentage was calculated as the ratio between VC volume and the volume of the region of interest. For the analysis, patients were divided into 3 groups according to VC percentage, from lowest to highest: group 1 (G1) included the first quartile of VCs, group 2 (G2) included the second and third quartiles, and group 3 (G3) included the fourth quartile. Risk of in-stent thrombosis was analysed using a multivariate model. Results: Thirty-nine patients were included (10 in G1, 19 in G2, and 10 in G3), and mean follow-up duration was 24 +/- 14.6 months. Patients in G1 and G3 had, respectively, a VC rate of < 1% (no VC) and >20% (severe VC). In G2, VC was considered to be intermediate. There was no statistical difference in the cardiovascular risk factors and preoperative medication. A significant difference was found for the healthy FP diameter between G1 (4.6 +/- 0.8 mm) and G3 (6.8 +/- 0.8 mm, P < 0.0001) and between G2 (5.2 +/- 1 mm) and G3 (P < 0.0001). The rate of drug-eluting stents was similar in all groups. There was no difference between groups concerning the rate of in-stent restenosis, target lesion revascularization, and target extremity revascularization. There was a higher rate of in-stent thrombosis for G1 versus G2 (P = 0.037), and no difference was noted between G1 versus G3 (P = 0.86) or G2 versus G3 (P = 0.12). G3 was associated with early stent thrombosis (< 1 month), while G1 was associated with late stent thrombosis (6-24 months). On multivariate analysis, only one predictive factor for stent thrombosis was found: patients with intermediate VC seemed to be protected against in-stent thrombosis (odds ratio = 0.27, 95% confidence interval: 0.1-0.77; P = 0.014). Conclusions: The study showed that VC quantification with CT imaging is feasible and useful for comparing outcomes following PAD endovascular revascularization. Below a certain threshold, the presence of VC might be necessary for plaque stability and may protect against
引用
收藏
页码:170 / 178
页数:9
相关论文
共 50 条
  • [31] Clinical impact of self-expandable stent diameter after femoropopliteal stenting
    Soga Y.
    Yokoi H.
    Urakawa T.
    Iwabuchi M.
    Nobuyoshi M.
    Cardiovascular Intervention and Therapeutics, 2011, 26 (1) : 38 - 44
  • [32] Comparison of Immediate and Midterm Outcome of Excimer Laser Assisted Spotted Stenting with Conventional Stenting in the Long Femoropopliteal Disease
    Wu, Tien-Yu
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 111 (07): : 48B - 48B
  • [33] The Clinical Impact of Restenosis After Femoropopliteal Stenting for Peripheral Arterial Occlusive Disease
    Huong Truong
    Montero-Baker, Miguel
    Branco, Bernardino C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (03) : S159 - S159
  • [34] Past, Present and Future of Femoropopliteal Stenting
    Schillinger, Martin
    Minar, Erich
    JOURNAL OF ENDOVASCULAR THERAPY, 2009, 16 : 147 - 152
  • [35] Bailout stenting in femoropopliteal arterial segment
    Boc, Anja
    Erzen, Barbara
    Perme, Rok Luciano
    Boc, Vinko
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2022, 51 (01) : 13 - 18
  • [36] Primary Nitinol Stenting for Femoropopliteal Disease
    Mewissen, Mark W.
    JOURNAL OF ENDOVASCULAR THERAPY, 2009, 16 : 63 - 81
  • [37] Intravascular Ultrasound for Femoropopliteal Stenting: Can It Predict Outcomes With Current-Generation Stents?
    Foley, T. Raymond
    Armstrong, Ehrin J.
    JOURNAL OF ENDOVASCULAR THERAPY, 2015, 22 (03) : 350 - 351
  • [38] Two-year Clinical Outcomes of Stent Fractures Following Primary Femoropopliteal Stenting
    Albayati, M. A.
    Shearman, C. P.
    Nordon, I. M.
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2013, 46 (05) : 601 - 601
  • [39] The evidence for stenting in femoropopliteal occlusive disease
    Minar, E.
    Schillinger, M.
    ACTA CHIRURGICA BELGICA, 2008, 108 (03) : 292 - 297
  • [40] Long-term clinical outcome and predictors of primary patency after femoropopliteal stenting
    Soga, Y.
    Iida, O.
    Hirano, K.
    Yokoi, H.
    Nanto, S.
    Muramatsu, T.
    Nobuyoshi, M.
    EUROPEAN HEART JOURNAL, 2010, 31 : 514 - 514